Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti–IL-6) in multiple myeloma

Because interleukin-6 (IL-6) is considered important in the proliferation of early multiple myeloma (MM), we hypothesized that the addition of the anti-IL-6 monoclonal antibody siltuximab to the bortezomib-melphalan-prednisone (VMP) regimen would improve outcomes in transplant-ineligible patients wi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: San-Miguel, Jesús, Bladé, Joan, Shpilberg, Ofer, Grosicki, Sebastian, Maloisel, Frédéric, Min, Chang-Ki, Polo Zarzuela, Marta, Robak, Tadeusz, Prasad, Sripada V. S. S., Tee Goh, Yeow, Laubach, Jacob, Spencer, Andrew, Mateos, María-Victoria, Palumbo, Antonio, Puchalski, Tom, Reddy, Manjula, Uhlar, Clarissa, Qin, Xiang, van de Velde, Helgi, Xie, Hong, Orlowski, Robert Z.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2014
Konular:
Clinical Trials and Observations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4123433/
https://ncbi.nlm.nih.gov/pubmed/24833354
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-12-546374
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller